Cidara Therapeutics Inc.

1.52+0.0400+2.70%Vol 334.64K1Y Perf -60.17%
Jul 30th, 2021 16:00 DELAYED
BID1.51 ASK1.52
Open1.56 Previous Close1.48
Pre-Market- After-Market1.54
 - -  0.02 1.32%
Target Price
6.40 
Analyst Rating
Strong Buy 1.33
Potential %
321.05 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-100/-50 
Value Ranking
     29.24
Insiders Value % 3/6/12 mo.
-/-100/80 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-100/82 
Income Ranking
 —    -
Market Cap73.40M 
Earnings Rating
Strong Sell
Price Range Ratio 52W %
2.08 
Earnings Date
12th Aug 2021

Today's Price Range

1.501.57

52W Range

1.464.34

5 Year PE Ratio Range

-3.50-1.40

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-0.65%
1 Month
-24.75%
3 Months
-31.53%
6 Months
-37.96%
1 Year
-60.17%
3 Years
-63.81%
5 Years
-87.22%
10 Years
-

TickerPriceChg.Chg.%
CDTX1.520.04002.70
AAPL145.860.22000.15
GOOG2 704.42-26.3900-0.97
MSFT284.91-1.5900-0.55
XOM57.57-1.3600-2.31
WFC45.94-0.5600-1.20
JNJ172.200.02000.01
FB356.30-2.0200-0.56
GE12.95-0.3400-2.56
JPM151.78-1.2200-0.80
Earnings HistoryEstimateReportedSurprise %
Q01 2021-0.17-0.39-129.41
Q04 2020-0.14-0.49-250.00
Q03 2020-0.48-0.4114.58
Q02 2020-0.24-0.45-87.50
Q01 2020-0.34-0.46-35.29
Q04 2019-0.29-0.42-44.83
Q03 20190.360.08-77.78
Q02 2019-0.51-0.493.92
Earnings Per EndEstimateRevision %Trend
6/2021 QR-0.270.00-
9/2021 QR-0.280.00-
12/2021 FY-1.19-9.17Negative
12/2022 FY-1.4312.27Positive
Next Report Date12th Aug 2021
Estimated EPS Next Report-0.27
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume334.64K
Shares Outstanding48.29M
Trades Count1.33K
Dollar Volume2.50M
Avg. Volume694.80K
Avg. Weekly Volume218.60K
Avg. Monthly Volume343.69K
Avg. Quarterly Volume411.39K

Cidara Therapeutics Inc. (NASDAQ: CDTX) stock closed at 1.52 per share at the end of the most recent trading day (a 2.7% change compared to the prior day closing price) with a volume of 336.60K shares and market capitalization of 73.40M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 68 people. Cidara Therapeutics Inc. CEO is Jeffrey Stein.

The one-year performance of Cidara Therapeutics Inc. stock is -60.17%, while year-to-date (YTD) performance is -24%. CDTX stock has a five-year performance of -87.22%. Its 52-week range is between 1.46 and 4.34, which gives CDTX stock a 52-week price range ratio of 2.08%

Cidara Therapeutics Inc. currently has a PE ratio of -0.90, a price-to-book (PB) ratio of 39.05, a price-to-sale (PS) ratio of 8.64, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -105.61%, a ROC of -207.59% and a ROE of -256.86%. The company’s profit margin is -%, its EBITDA margin is -629.90%, and its revenue ttm is $8.55 Million , which makes it $0.18 revenue per share.

Of the last four earnings reports from Cidara Therapeutics Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.27 for the next earnings report. Cidara Therapeutics Inc.’s next earnings report date is 12th Aug 2021.

The consensus rating of Wall Street analysts for Cidara Therapeutics Inc. is Strong Buy (1.33), with a target price of $6.4, which is +321.05% compared to the current price. The earnings rating for Cidara Therapeutics Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Cidara Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Cidara Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 12.75, ATR14 : 0.09, CCI20 : -71.95, Chaikin Money Flow : -0.15, MACD : -0.13, Money Flow Index : 26.22, ROC : -10.59, RSI : 31.79, STOCH (14,3) : 14.29, STOCH RSI : 1.00, UO : 41.40, Williams %R : -85.71), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Cidara Therapeutics Inc. in the last 12-months were: James E. Levine (Buy at a value of $100 720), Jeffrey Stein (Buy at a value of $100 015), Jessica Oien (Sold 2 001 shares of value $4 828 ), Neil Abdollahian (Sold 4 337 shares of value $9 816 ), Paul Daruwala (Sold 3 461 shares of value $7 485 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
4 (66.67 %)
4 (66.67 %)
4 (66.67 %)
Moderate Buy
2 (33.33 %)
2 (33.33 %)
2 (33.33 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.33
Strong Buy
1.33
Strong Buy
1.33

Cidara Therapeutics Inc.

Cidara Therapeutics Inc is a biotechnology company. It is focused on the discovery, development, and commercialization of novel anti-infectives for the treatment and prevention of diseases. The company's main drug constitutes echinocandins antifungals in the form of CD101IV and CD101 topical. It has developed a proprietary immunotherapy technology platform, Cloudbreak, which is used to create compounds designed to direct a patient's immune cells to attack and eliminate pathogens that cause infectious diseases.

CEO: Jeffrey Stein

Telephone: +1 858 752-6170

Address: 6310 Nancy Ridge Drive, San Diego 92121, CA, US

Number of employees: 68

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

86%14%

Bearish Bullish

52%48%

Bearish Bullish

57%43%

News

Stocktwits